GE HealthCare and DocPanel are collaborating to provide clinicians with peer-to-peer advanced reader training for Cerianna, designed to enhance diagnostic confidence in complex cases. 

How to access your peer-to-peer advanced reader training

1

Register
Complete the form below to enroll in the program

2

Account set-up
A DocPanel representative will connect with you within 48 hours to walk you through the process

3

Submit scans
Upload your Cerianna PET/CT scans securely through DocPanel’s platform

4

Consult with experts
Schedule a peer-to-peer consultation with a DocPanel nuclear medicine specialist to review findings

5

Apply insight
Use the expert feedback to support you in your clinical decision-making

Why use Cerianna peer-to-peer advanced reader training with DocPanel?

Register for peer-to-peer advanced reader training

*Disclaimer: Completion of Reader Training is required to access this program. GE HealthCare offers an option for reader training on the Cerianna website. DocPanel does not provide medical advice, judgments, or diagnoses. Healthcare providers and their institutions are solely responsible for all patient-related decisions, including image capture, interpretation, diagnosis, treatment, and management. Participation is limited to three program sessions per healthcare provider.

About GE HealthCare and DocPanel

GE HealthCare is a global leader
in medical technology and
pharmaceutical diagnostics,

advancing precision care through innovations like
Cerianna, the only FDA-approved imaging agent
reflecting the binding ability of estradiol to the
estrogen receptor in recurrent or metastatic breast cancer lesions.

DocPanel is a premier network of board-certified
radiologists and nuclear medicine specialists,
providing expert diagnostic support to healthcare
professionals worldwide.

Together, we’re empowering clinicians to deliver exceptional patient outcomes.

Learn more about Cerianna

Cerianna on demand reader training

Cerianna live reader training

About Cerianna

Cerianna reflects the potential binding ability of estradiol to the estrogen receptor, offering high diagnostic accuracy to detect ER-positive lesions in recurrent or metastatic breast cancer. 

IMPORTANT SAFETY INFORMATION

INDICATIONS AND USAGE

CERIANNA is indicated for use with positron emission tomography (PET) imaging for the detection of estrogen receptor (ER)-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer.

 LIMITATIONS OF USE

Tissue biopsy should be used to confirm recurrence of breast cancer and to verify ER status by pathology. CERIANNA is not useful for imaging other receptors, such as human epidermal growth factor receptor 2 (HER2) and the progesterone receptor (PR).

CONTRAINDICATIONS

None.

ADVERSE REACTIONS

In clinical trials evaluating the safety of CERIANNA in patients with breast cancer (n=1207), the following adverse reactions occurred at a rate < 1%: injection-site pain and dysgeusia.

 To report SUSPECTED ADVERSE REACTIONS, contact Zionexa US Corp, a GE HealthCare Company at +1.800.654.0118 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

For full Prescribing Information, click here.